Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | -192.38K | -238.87K | -227.64K | -207.93K |
EBITDA | -44.22M | -38.77M | -28.67M | -23.98M | -15.15M |
Net Income | -44.58M | -37.98M | -28.60M | -23.97M | -14.76M |
Balance Sheet | |||||
Total Assets | 25.47M | 12.08M | 21.59M | 37.20M | 58.66M |
Cash, Cash Equivalents and Short-Term Investments | 23.29M | 9.56M | 19.87M | 35.70M | 57.17M |
Total Debt | 494.00K | 552.98K | 603.83K | 301.74K | 421.64K |
Total Liabilities | 11.18M | 25.85M | 6.08M | 4.16M | 3.86M |
Stockholders Equity | 14.29M | -15.16M | 15.51M | 33.05M | 54.79M |
Cash Flow | |||||
Free Cash Flow | -47.69M | -33.24M | -25.45M | -22.71M | -14.00M |
Operating Cash Flow | -47.58M | -32.38M | -25.22M | -22.57M | -13.93M |
Investing Cash Flow | -104.19K | -864.04K | -225.97K | -141.36K | -62.35K |
Financing Cash Flow | 61.41M | 22.94M | 9.61M | 1.25M | 60.55M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
51 Neutral | $7.50B | 0.32 | -61.87% | 2.27% | 17.10% | 1.59% | |
51 Neutral | $20.80M | ― | -49.39% | ― | 473.46% | 62.25% | |
44 Neutral | $33.35M | ― | -197.11% | ― | ― | ― | |
42 Neutral | $14.34M | ― | -122.28% | ― | ― | ― | |
34 Underperform | $8.57M | ― | -208.72% | ― | ― | 56.38% | |
34 Underperform | $7.59M | ― | -616.17% | ― | ― | 71.39% | |
33 Underperform | $22.43M | ― | -78.32% | ― | ― | 47.73% |
On March 12, 2025, Cellectar Biosciences’ board approved amendments to the employment agreements of its CEO and COO, enhancing their severance benefits in the event of a change in control. Additionally, on March 11, 2025, the board adopted new by-laws to align with Delaware law, revising stockholder nomination procedures and reducing the quorum requirement for meetings.